Neurocrine Biosciences, Inc.

Smithkline Beecham (cork) Ltd

Sb Cork

Smithkline Beecham Corporation

John Edward Tellew

Marion Lanier

John Patrick Williams

Manisha Moorjani

Zhiyong Luo

John P Williams

Xiaohu Zhang

Xiahou Zhang

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R, R, R, Y, Het, n, o, R, Ar and Rare as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Pyrazolo[1,5-alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R, R, n, R, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonists in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

CRF receptor antagonists and methods relating thereto

Growing community of inventors

San Diego, CA, United States of America

John Edward Tellew